arrow
L

Lisa G. Horvath

australia and new zealand urogenital and prostate cancer trials group
H指数:64
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Insulin-Like Growth Factor Axis and Survival in Metastatic Hormone-Sensitive Prostate Cancer: Post-Hoc Analysis From the ENZAMET Phase 3 Trial

胰岛素样生长因子轴与转移性激素敏感型前列腺癌的生存:来自ENZAMET III期试验的事后分析

2026-09-300
OAAI
Patient-derived models of prostate cancer: Capturing tumour complexity from initiation to metastasis

患者来源的前列腺癌模型:从起始到转移捕捉肿瘤复杂性

2026-08-010
OAAI
EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression

EMETPRO:一项多中心、国际性回顾性分析,评估早期进展的转移性激素敏感性前列腺癌患者

2026-05-290
PRE
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

阿贝西利布联合阿比特龙在转移性去势抵抗性前列腺癌患者中的研究(CYCLONE 2):一项随机、双盲、安慰剂对照、Ⅲ期临床试验

2025-10-270
PRE
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)

循环脂质面板PCPro与转移性激素敏感前列腺癌临床结局的关联:ENZAMET III期随机试验(ANZUP 1304)的事后分析

2025-05-200
PRE
Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study

Xaluritamig,一种STEAP1 x CD3 XmAb 2+1免疫疗法,在转移性去势抵抗性前列腺癌(mCRPC)患者(pts)中的初步研究结果:来自一项I期研究剂量扩展队列的数据

2024-09-010
PRE
Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig

循环肿瘤细胞(CTC)计数和总生存期(OS)在用xaluritamig治疗的转移性去势抵抗性前列腺癌(mCRPC)男性患者中的情况

2024-09-010
PRE
Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)

ENZAMET(ANZUP 1304)研究中,转移性激素敏感性前列腺癌(mHSPC)高容量亚组内的临床预后因素

2024-09-010
PRE